Nanoform
Nanoform Finland Plc is a Helsinki-based pharmaceutical nanotechnology company that uses its proprietary Nanoforming platform to develop nanoformed medicines and provide cGMP contract manufacturing, serving pharmaceutical companies through licensing, R&D collaborations, and API supply.
- Company typePrivate
- Founded2015
- HeadquartersHelsinki, Finland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nanoform does
Nanoform Finland Plc is a Helsinki-based, publicly listed (Nasdaq Helsinki: NANOFH) pharmaceutical nanotechnology company that uses a proprietary Nanoforming Technology platform to reduce active pharmaceutical ingredients (APIs) to the nanoscale, improving drug solubility and bioavailability. The company was founded in 2015 and operates with a headcount of 101-250 employees. Its product portfolio comprises three branded nanoformed drug candidates — Nanoenzalutamide (with a planned first European market launch in 2028), Nanoapalutamide (in clinical development, supported by a EUR 5M Business Finland R&D loan), and Nanotrastuzumab (which the company reports matches the performance of Herceptin Hylecta) — alongside cGMP contract manufacturing services for nanoformed APIs used in clinical trials and commercial supply. The Nanoforming Technology addresses one of the most cited challenges in pharmaceutical development: poor aqueous solubility of active compounds, which limits bioavailability of roughly 40% of new chemical entities.
Nanoform firmographics
Firmographics- Name
- Nanoform
- Legal name
- Nanoform Finland Plc
- Website
- https://nanoform.fi
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Nanoform Finland Plc is a Helsinki-based pharmaceutical nanotechnology company that uses its proprietary Nanoforming platform to develop nanoformed medicines and provide cGMP contract manufacturing, serving pharmaceutical companies through licensing, R&D collaborations, and API supply.
- Ownership category
- akta.pro rank
Nanoform industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Nanotechnology (541713), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
- akta.pro secondary industries
- Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
Keywords
Where Nanoform is headquartered
LocationHeadquarters
- HQ city
- Helsinki
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
Nanoform business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- NanoImproved Medicines Commercialization: Revenue from commercialization of proprietary nanoformed medicines including Nanoenzalutamide and Nanoapalutamide. First European market launch planned for 2028.
- Contract Manufacturing Services: Manufacturing and licensing of nanoformed APIs for clinical trials and commercial supply under cGMP certifications.
- R&D Collaboration and Licensing: Research and development partnerships with pharmaceutical companies for nanoparticle-enabled formulation platforms.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Nanoform product offering
Product offeringCore offering
Nanoform develops and manufactures nanoformed pharmaceutical products using its proprietary nanoparticle-enabled formulation technology, which improves the bioavailability and performance of active pharmaceutical ingredients (APIs). The company produces proprietary branded nanoformed medicines such as Nanoapalutamide, Nanoenzalutamide, and Nanotrastuzumab, and provides cGMP-compliant contract manufacturing services for nanoformed APIs for clinical trials and commercial supply.
Product overview
Nanoform operates as a nanomedicine company developing nanoformed pharmaceutical products and providing nanoparticle-enabled formulation services. The product portfolio includes branded nanoformed medicines such as Nanoapalutamide, Nanoenzalutamide, and Nanotrastuzumab, alongside GMP contract manufacturing services for nanoformed APIs. The company holds European commercial cGMP manufacturing licenses from FIMEA and is expanding manufacturing capabilities in the US market.
Differentiator
Problem solved
Functional benefit
Brands
- NanoImproved medicines: Nanoformed pharmaceutical products that improve drug performance through nanoparticle formulations.
- Nanoapalutamide
- Nanoenzalutamide
- Nanotrastuzumab
Products and services
- Nanoapalutamide
- Nanoenzalutamide
- Nanotrastuzumab
- GMP Manufacturing Services
Quantifiable outcome
- Nanotrastuzumab matches performance of Herceptin Hylecta
- +1 more outcomes
Companies that use Nanoform
Customer profileSegments1 record
Ideal customer profiles1 record
Nanoform technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Nanoform partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Unnamed PartnerscoreNanoform announced new partnerships focused on advancing localized therapy and high-concentration biologics delivery. The partnerships aim to leverage Nanoform's nanoforming technology for specialized pharmaceutical applications.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Nanoform competitors and assessment
Company assessmentDirect peers
- Starpharma: Australia-listed company developing dendrimer-based nanoparticle drug delivery and DEP platform partnerships with major pharma. A direct comparable to Nanoform's platform-plus-partnerships business model in nanomedicine.
- Camurus: Swedish specialty pharma company developing nanoparticle/fluid-crystal drug delivery formulations for improved bioavailability. Closely comparable to Nanoform as a Nordic-headquartered nanomedicine peer with both proprietary products and partnered formulation programs.
- Cristal Therapeutics: European (Netherlands-based) clinical-stage company developing polymeric nanoparticle drug conjugates (CriPec platform) for oncology. Directly comparable to Nanoform as a nanoparticle-formulation platform targeting improved drug delivery.
- NanoCarrier: Japanese clinical-stage biopharma developing micellar and nanoparticle drug delivery systems for oncology and other indications. Directly comparable to Nanoform in applying nanoparticle engineering to improve drug performance and delivery.
Others
Emerging players
- CytoSorbents: US clinical-stage medtech/biotech using nanoporous polymer bead technology in therapeutic applications. Comparable as a small-cap public nanomedicine player with proprietary bead/particulate platform targeting pharma and critical care applications.
- Ascendia Pharma: US-based specialty CDMO offering nanoemulsion, nanosuspension, and amorphous solid dispersion formulation development for poorly soluble drugs. Comparable to Nanoform's nanoforming platform and contract manufacturing services targeting bioavailability challenges.
Broad incumbents
- Catalent: Large global pharma services CDMO offering formulation, bioavailability enhancement, and cGMP manufacturing including particle engineering. A broad incumbent comparable to Nanoform's contract manufacturing and formulation platform offering at materially larger scale.
- Lonza (Bend Research): Global CDMO offering formulation development, particle engineering, and cGMP manufacturing for poorly soluble drugs via its Bend Research heritage. A broad incumbent comparable to Nanoform across the formulation-to-commercial-supply chain at greater scale.
- PCI Pharma Services: Global CDMO providing drug development, manufacturing, and packaging services including specialized formulation and clinical-to-commercial supply. Comparable to Nanoform's cGMP manufacturing services for nanoformed APIs targeting pharma customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Nanoform social profiles
Digital presenceNanoform compliance and trust
Trust signalCompliance2 records
Nanoform financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nanoform leadership team
Management profileNumber of profiles
Profiles2 records
Nanoform funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nanoform M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nanoform
What does Nanoform do?
Nanoform develops and manufactures nanoformed pharmaceutical products using its proprietary nanoparticle-enabled formulation technology, which improves the bioavailability and performance of active pharmaceutical ingredients (APIs). The company produces proprietary branded nanoformed medicines such as Nanoapalutamide, Nanoenzalutamide, and Nanotrastuzumab, and provides cGMP-compliant contract manufacturing services for nanoformed APIs for clinical trials and commercial supply.
Is Nanoform a public or private company?
Nanoform is a private company. It is classified as public and is currently operating.
When was Nanoform founded?
Nanoform was founded in 2015. It employs 101 to 250 people.
Where is Nanoform based?
Nanoform is headquartered in Helsinki, Finland, in the Europe region.
How does Nanoform make money?
Three revenue lines are on record. NanoImproved Medicines Commercialization is the primary driver. The others are contract Manufacturing Services and R&D Collaboration and Licensing.
Who are Nanoform's main competitors?
Direct peers on record are Starpharma, Camurus, Cristal Therapeutics and NanoCarrier. Quotient Sciences is listed as an others. Emerging players are CytoSorbents and Ascendia Pharma. Broad incumbents are Catalent, Lonza (Bend Research) and PCI Pharma Services.
Does Nanoform have an API?
No public API is recorded for Nanoform.
What industry is Nanoform in?
Nanoform's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.